Lixte Biotechnology (NASDAQ:LIXT) Shares Up 11.6% – Should You Buy?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s share price rose 11.6% during mid-day trading on Thursday . The company traded as high as $2.84 and last traded at $2.80. Approximately 3,554 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 18,790 shares. The stock had previously closed at $2.51.

Lixte Biotechnology Trading Down 12.1 %

The stock has a market cap of $5.54 million, a P/E ratio of -1.42 and a beta of -0.04. The company has a 50 day simple moving average of $2.25 and a 200 day simple moving average of $2.03.

Lixte Biotechnology (NASDAQ:LIXT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.44) earnings per share for the quarter.

Institutional Investors Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC acquired a new stake in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned about 0.56% of Lixte Biotechnology as of its most recent SEC filing. Institutional investors own 5.10% of the company’s stock.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.